Fierce Healthcare
NOVEMBER 5, 2021
Nearly 32,000 Kaiser Permanente workers set to strike Nov. 15. Tens of thousands more mulling their own demonstrations. dmuoio. Fri, 11/05/2021 - 10:58.
pharmaphorum
NOVEMBER 3, 2021
A real-world study of digital therapeutic (DTx) for opioid use disorder has found that patient show used it had 46% fewer hospital stays than a control group, saving more than $2,700 over a nine-month period. The study of Pear Therapeutics’ reSET-O found that the total cost of hospital and clinician costs were $11,141 among 64 patients who were prescribed the DTx but didn’t use it, but fell to $8,733 among active users of the 12-week course.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
NOVEMBER 3, 2021
In the last 2 years, and accelerated by Covid, native advertising has exploded across healthcare for DTC and HCP marketing. Native ads have been adopted by all healthcare industries including pharma, device, health systems, retailers, pharmacies, payers, and the gamut of regional service providers. But there are still a handful of advertiser holdouts, and they are missing out on highly engaged audiences.
Outsourcing Pharma
NOVEMBER 1, 2021
The cloud software firmâs Digital Clinical Trials Survey Report reveals that the industry is adapting to challenges caused by COVID-19 and other factors.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Healthcare
NOVEMBER 3, 2021
Former Livongo exec launches women's health startup that uses data for personalized care. hlandi. Wed, 11/03/2021 - 11:24.
pharmaphorum
NOVEMBER 1, 2021
Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer. Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in August at 1.43 million yen (around $12,500) per dose, according to a Pharma Japan report.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Outsourcing Pharma
NOVEMBER 1, 2021
A former employee of Tellus Clinical Research in Miami has admitted to charges related to a conspiracy to falsify data on a list of clinical drug trials.
Fierce Healthcare
NOVEMBER 3, 2021
Notable nabs $100M to automate administrative tasks in healthcare, boosts valuation to $600M. rtorrence. Wed, 11/03/2021 - 11:07.
pharmaphorum
NOVEMBER 5, 2021
An oral antiviral drug developed by Pfizer has been shown to dramatically cut the risk of hospitalisation or death from COVID-19 when given in the early stages of infection. The phase 3 trial found that Paxlovid – which combines new protease inhibitor PF-07321332 with already-approved HIV drug ritonavir – reduced the risk of hospitalisation or death by 89% when given to newly-diagnosed adults who were at risk of developing severe COVID-19 in the EPIC-HR trial.
Pharma Times
NOVEMBER 1, 2021
Anyone who received their second dose at least six months ago can now receive their booster at one of these sites
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
NOVEMBER 1, 2021
The trial will evaluate a weekly regimen of islatravir and lnecapavir in HIV patients who are virologically suppressed while on antiretroviral therapies.
Fierce Healthcare
OCTOBER 31, 2021
Medicare drops end-stage renal disease payment rule that aims to close health equity gaps. hlandi. Sun, 10/31/2021 - 16:09.
pharmaphorum
NOVEMBER 1, 2021
Novartis has claimed FDA approval for one of its ‘wild card’ drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML). Scemblix (asciminib) was one of a clutch of high risk, high reward drug candidates for a range of diseases that Novartis chief executive Vas Narasimhan said last year were flying under-the-radar of industry watchers, but could potentially develop into blockbusters.
Pharma Times
NOVEMBER 2, 2021
Indonesia becomes the first country to authorise the vaccine
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Outsourcing Pharma
NOVEMBER 2, 2021
The global pharmaceutical industry event is returning to the real world November 9-11 this year, with online content for professionals opting not to travel.
Fierce Healthcare
NOVEMBER 5, 2021
UnitedHealth Group again the most profitable payer in Q3. pminemyer. Fri, 11/05/2021 - 14:32.
pharmaphorum
NOVEMBER 5, 2021
Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying to challenge antibody-based therapies for diseases associated with the complement pathway. A phase 2 trial of iptacopan in patients with the rare kidney disease C3 glomerulopathy (C3G) – which causes progressive kidney failure and has no approved treatments – showed reductions in kidney damage with the drug that Novartis said were “clinically important.” C3G of
Pharma Times
NOVEMBER 5, 2021
The trial evaluated the investigational medicine in non-hospitalised adult patients with COVID-19 who are at high-risk of progressing to severe illness
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
NOVEMBER 2, 2021
An expert from the specialty chemicals firm (and CPhI Worldwide speaker) explains trends and developments in excipients and how they drive advancements.
Fierce Healthcare
NOVEMBER 5, 2021
Industry Voices—Let's stop calling it medical 'debt'. pminemyer. Fri, 11/05/2021 - 11:38.
pharmaphorum
NOVEMBER 4, 2021
After more than 20 years, Novartis has finally decided to sell its substantial share in fellow Swiss pharma group Roche for $20.7 billion, a decent return on its original $5 billion investment. The agreement will see Novartis lose its one-third voting share stake in Roche, after agreeing to sell 53.3 million Roche bearer shares at their average price over 20 days prior to 2 November, when the deal was agreed.
Pharma Times
NOVEMBER 5, 2021
Forxiga becomes the first new treatment option for CKD patients in nearly 20 years
Pharma Marketing Network
NOVEMBER 4, 2021
Jim Lefevere is an award-winning highly-influential agile intrapreneur with over 20 years of expertise in the consumer goods, startups, medical device, and healthcare industries. Jim has enjoyed a very diverse and successful career with progressive growth in leadership, global marketing, digital marketing, and strategy development. Jim is a visionary intrapreneur at a global scale as a social media pioneer, digital health scholar, and agile leader.
Fierce Healthcare
NOVEMBER 2, 2021
CMS physician fee schedule rule cuts payments, expands telehealth reimbursement past 2023. rking. Tue, 11/02/2021 - 17:16.
pharmaphorum
NOVEMBER 4, 2021
Routine vaccination with human papillomavirus vaccines have resulted in an 87% reduction in cervical cancer cases in England, and could even see the need for smear tests phased out in future, according to a new study. The jabs with have been offered by the NHS to girls between the ages of 12 and 13 since 2008, with more than 10 million doses administered since then, and from September 2019 was also offered to boys in the same age group.
Pharma Times
NOVEMBER 1, 2021
HRT treats menopause symptoms by replacing hormones that are at a lower level for those experiencing it
Outsourcing Pharma
NOVEMBER 4, 2021
Novartis, which has been a shareholder in Roche for more than 20 years, will sell its stake in the business to Roche for $20.7bn.
Fierce Healthcare
NOVEMBER 3, 2021
AMIA 2021: Understanding how technology impacts patients and providers. agliadkovskaya. Wed, 11/03/2021 - 12:10.
pharmaphorum
OCTOBER 31, 2021
The FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that typically starts in middle age and involves difficulty in focusing on near objects. The approval has been granted to Vuity (formerly AGN-190584 ), a one-daily eyedrop formulation of muscarinic cholinergic agonist pilocarpine developed by AbbVie’s Allergen unit that is now an alternative to reading glasses, contact lenses or laser eye surgery for the disorder.
Pharma Times
NOVEMBER 2, 2021
Belgium leads in country rankings by the value of exports this year, followed by Germany and the US
Outsourcing Pharma
NOVEMBER 4, 2021
This monthâs announcements of programs, names, appointments, hires, and other happenings includes items from Emmes, Science 37, Cerner and other companies.
Fierce Healthcare
NOVEMBER 2, 2021
Hundreds of organizations urge governors to extend telehealth licensure flexibilities. rtorrence. Tue, 11/02/2021 - 14:32.
pharmaphorum
NOVEMBER 5, 2021
In the latest episode of the podcast Dominic Tyer speaks with Pierre Bourdage, who’s global head of biopharmaceuticals at Sandoz about the big issues in biosimilars. They look at how biosimilars are changing healthcare and what the market looks like today, as well as Sandoz’s involvement in the area and the company’s future plans in biosimilars. It’s an episode that covers the regulatory position of biosimilars, uptake of these medicines by healthcare professionals and what biosimilars need next
Expert insights. Personalized for you.
145 
Let's personalize your content